Advanced Renal Cell Carcinoma Treatment Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Advanced Renal Cell Carcinoma Treatment Market Grown from 2024 to 2025?
The market for advanced renal cell carcinoma treatment has seen substantial growth in the recent past and is projected to expand from $8.10 billion in 2024 to $8.75 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historical period include the rise in the elderly population, the escalating number of smokers, the growth in hypertension incidents, heightened health care spending, and the surge in renal cancer diagnoses.
What Growth Rate Is Anticipated for the Advanced Renal Cell Carcinoma Treatment Market in the Coming Years?
In the coming years, the market for advanced renal cell carcinoma treatment is anticipated to experience significant growth. The market is projected to expand to $11.77 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%. The predicted growth in the forecasted period is due to the escalating number of genetic conditions, an increased prevalence of chronic high blood pressure, the use of tyrosine kinase inhibitors, heightened awareness about kidney cancer, and increased investment in research and development. Key trends expected in the forecast period include advancements in diagnostic technology, novel targeted therapies, oral therapies development, progression in liquid biopsy technology, and the utilization of artificial intelligence in the creation of new drugs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21090&type=smp
Who Are the Leading Companies in the Advanced Renal Cell Carcinoma Treatment Market?
Major companies operating in the advanced renal cell carcinoma treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen SA, Exelixis Inc., BeiGene Ltd., Bavarian Nordic A/S, Telix Pharmaceuticals Limited, CRISPR Therapeutics AG, Beijing Scitech-Mq Pharmaceuticals Limited, HUTCHMED (China) Limited, Arcus Biosciences Inc., NGM Biopharmaceuticals Inc., Mirati Therapeutics Inc.
What Are the Key Drivers of the Advanced Renal Cell Carcinoma Treatment Market?
The growth of the advanced renal cell carcinoma (RCC) treatment market is predicted to be fuelled by the surge in genetic disorders. Genetic disorders are diseases or disorders caused by DNA abnormalities in a person, which can be inherited from either or both parents, or be a result of mutations occurring throughout a person’s life. The rising incidence of these disorders is linked to factors like improvements in diagnostic technology, heightened awareness and reporting, as well as changes in environment and lifestyle that may interact with genetic predispositions. Advanced RCC treatments tackle these genetic conditions by targeting specific molecular pathways. This brings about the development of personalised therapies that address the genetic elements contributing to tumour development and growth. For example, Gene People, a registered charity based in the UK, reported in June 2023 that 1 child in every 25 suffers from a genetic disorder, translating to over 2.4 million people living with a genetic disorder in the UK. Further, approximately 30,000 newborns and children are diagnosed with genetic disorders each year in the UK. Thus, the increasing prevalence of genetic disorders is propelling the advanced RCC treatment market’s expansion.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21090&type=smp
What Are the Key Market Segments in the Advanced Renal Cell Carcinoma Treatment Industry?
The advanced renal cell carcinoma treatment market covered in this report is segmented –
1) By Treatment: Biologics, Radiation Therapy, Chemotherapy, Hormone, Vaccine Therapy, Other Treatments
2) By Route Of Administration: Parental, Oral, Other Route Of Administrations
3) By End User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Biologics: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cytokine Therapy, Targeted Small Molecule Inhibitors
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Beam Therapy
3) By Chemotherapy: Platinum-Based Chemotherapy, Antimetabolites, Alkylating Agents
4) By Hormone Therapy: Androgen Deprivation Therapy (ADT), Estrogen Receptor Modulators
5) By Vaccine Therapy: Peptide-Based Cancer Vaccines, Dendritic Cell Vaccines, DNA-Based Cancer Vaccines
6) By Other Treatments: Cryoablation, Radiofrequency Ablation (RFA), Combination Therapy
What Are the Latest Trends in the Advanced Renal Cell Carcinoma Treatment Market?
Leading firms in the sophisticated renal cell carcinoma (RCC) therapy industry are concentrating their efforts on creating new and innovative products like hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors. The goal behind this innovative development is to enhance the effectiveness of the treatment and to improve patient experiences and outcomes. These HIF-2α inhibitors are a unique class of drugs that are designed to restrain the activity of HIF-2α, a significant protein that manages the body’s response to low levels of oxygen. For example, in December 2023, Merck & Co. Inc., an American healthcare firm, was granted approval by the U.S. Food and Drug Administration (FDA) for their oral HIF-2α inhibitor, WELIREG (belzutifan). This pioneering therapy is specifically designed for those patients who have previously undergone treatment with PD-1 or PD-L1 inhibitors and VEGF-TKI therapies. This FDA approval is significant as it introduces a new therapeutic method for a patient group with restricted treatment options, offering them a glimmer of hope for improved results and better management of advanced RCC.
Access The Full Report Here:
What Are the Key Regional Markets in the Advanced Renal Cell Carcinoma Treatment Industry?
North America was the largest region in the advanced renal cell carcinoma treatment market in 2024. The regions covered in the advanced renal cell carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21090
This Report Delivers Insight On:
1. How big is the advanced renal cell carcinoma treatment market, and how is it changing globally?
2. Who are the major companies in the advanced renal cell carcinoma treatment market, and how are they performing?
3. What are the key opportunities and risks in the advanced renal cell carcinoma treatment market right now?
4. Which products or customer segments are growing the most in the advanced renal cell carcinoma treatment market?
5. What factors are helping or slowing down the growth of the advanced renal cell carcinoma treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
